Cuffe Michael S.

HCA Chief Clinical Officer Cuffe sold 3,836 shares at $418.84 for $1.6M, reducing HCA stake by -10.9%.

Cuffe Michael S., EVP and Chief Clinical Officer, sold 3,836 shares (3.8K shares) of HCA Healthcare, Inc. (HCA) at $418.84 on 2025-09-08 for total value of $1,606,670.24 ($1.6M), reducing his post-transaction holdings to 31,502 shares (31.5K shares) from pre-transaction 35,338 shares (35.3K shares), a net reduction of -10.9% vs pre-transaction holdings. The sale occurs as HCA trades at $418.10, just -0.6% from its 52-week high of $420.77 and up +9.6% over the past 30 days and +14.6% over 90 days, reflecting strong recent momentum. Examining his same-ticker history at HCA across 3 prior sells, 2 of 3 prior sells were well-timed at the 90-day mark, though outcomes vary: a 2024-09-12 sale had -18.2% 90d return (well-timed), while a 2024-05-09 sale had +11.2% 90d return (poorly timed). This current sale near the 52-week high deserves tracking to assess whether this executive's pattern of measured occasional sales at inflated valuations continues.

HCA EVP Chief Clinical Officer Cuffe sells 8,358 shares (22.0% of holdings) at $385.42 for $3.2M

Cuffe Michael S., EVP and Chief Clinical Officer, sold 8,358 shares of HCA Healthcare on 2024-09-12 at $385.42, reducing his holdings from 38,036 to 29,678 shares (a 22.0% reduction). The sale occurred near the 52-week high of $397.75 (-1.5% from peak) and follows HCA's strong recent performance: +6.2% over 30 days and +16.1% over 90 days. Across his cross-ticker sell history, Cuffe's timing record shows an average 90-day return of +4.2% with a well-timed rate of 50.00%, indicating mixed success at timing market peaks. At HCA specifically, his prior two sales (May 2024 and April 2023) produced divergent outcomes: the May sale was followed by +6.5% (30d) and +11.2% (90d) gains, while the April 2023 sale preceded a -7.0% (30d) and -2.8% (90d) decline, showing 1 of 2 prior sales at this ticker were well-timed at the 90-day mark. The company fundamentals remain solid with $17.5B in revenue, $1.5B net income, 7.9% annual revenue growth, and a moderate P/E of 17.62.